Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | ALPG | P10696 | 1/20 | 0.42 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.40 |
| ▸ | MT-CO2 | P00403 | 3/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | TOP1 | P11387 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6740970 | 0.87 | ALPL (0.43) | ALPLALPGPLAAHSD17B10EGFR | |
| SCHEMBL6739651 | 0.82 | KMT2A (0.47) | HSD17B10KMT2A | |
| SCHEMBL6740772 | 0.82 | CHRM4 (0.56) | CHRM4 | |
| SCHEMBL6743861 | 0.81 | TSHR (0.39) | ALPLALPGPLAACHRM4HSD17B10 | |
| SCHEMBL6743052 | 0.81 | ESR1 (0.49) | HSD17B10KMT2A | |
| SCHEMBL6743539 | 0.80 | CCNB2 (0.47) | CHRM4KMT2A | |
| SCHEMBL6742507 | 0.79 | MAPT (0.36) | ALPLALPGPLAAHSD17B10KMT2A | |
| SCHEMBL6740546 | 0.79 | ESR1 (0.45) | HSD17B10EGFRKMT2A | |
| SCHEMBL6744013 | 0.78 | HSD17B10 (0.37) | CHRM4HSD17B10EGFRKMT2A | |
| SCHEMBL6741864 | 0.78 | ALDH1A1 (0.42) | ALPLALPGPLAAHSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818642-B2 | CAMPYLOBACTER INFECTION TREATMENT | ALTANA PHARMA AG (DE) | 2004-11-16 | — | — | US | disclosed |
| US-20040152714-A1 | Benzylaminopyrimidines | ALTANA PHARMA AG (DE) | 2004-08-05 | — | — | US | disclosed |
| EP-1395594-A1 | NEW BENZYLAMINOPYRIMIDINES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002094832-A1 | NEW BENZYLAMINOPYRIMIDINES | ALTANA PHARMA AG (DE) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152714-A1 | Benzylaminopyrimidines | DPYD, PGLS, TPMT | ALPL 3389/4885ALPG 2655/4885PLAA 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.